SLC5A2 and cardiac arrest: SGLT2 inhibitor use was associated with a significantly lower number of cardiac arrests (656 vs. 902) compared to non‐use (HR 0.70 [95% CI 0.63‐0.78]; log‐rank P value 0.001 [Table 3]).